DOCSLIB.ORG

Alphabetical Listing of Chemicals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alphabetical Listing of Chemicals ALPHABETICAL LISTING OF CHEMICALS Product Description Specific Solvent/ Catalog Number/ A Activity Concentration Package Size (±)- cis, trans -Abscisic acid “cold” Solid ARCD 0555- 250 mg B (5-[1-Hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]- ARCD 0555- 500 mg 3 methyl-[2Z,4E]-pentdienoic acid) ARCD 0555- 1 g M.W. 264.3 ARCD 0555- 5 g C CAS # 14375-45-2 ARCD 0555- 30 g Synthetic D (±)- trans, trans Abscisic acid “cold” Solid ARCD 0572- 50 mg (5-[1-Hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl] ARCD 0572- 250 mg E 3 methyl-[2E,4E]-pentadienoic acid) M.W. 264.3 F CAS # 6755-41-5 Synthetic G Exclusive (+)-Abscisic acid “cold” Solid ARCD 0780- 1 g H M.W. 264.3 ARCD 0780- 10 g Natural, isolated from plant gibberellins I Exclusive Acacetin “cold” Solid ARCD 0752- 10 mg J C16 H12 O5 M.W. 284.26 K CAS # 480-44-4 13 N-Acetoxyphthalimide [1,2- C2] “stable isotope” Ethyl acetate ARCD 1183- 1 mg L M.W. 207.2 in sealed ampoule ARCD 1183- 5 mg Exclusive 1 mg/ml M Acetyl Coenzyme A lithium salt “cold” Solid ARCD 0294- 10 mg (cis,cis,cis,cis -5,8,11,14-Eicosatetraenoyl Coenzyme A lithium salt) ARCD 0294- 25 mg N M.W 809.57 ARCD 0294- 100 mg Shipped in Dry Ice O Acetyl [1- 13 C] Coenzyme A lithium salt “stable isotope” Solid ARCD 1016- 1 mg . C2C21 H38 N7O17 P3S xLi P M.W. 809.57 (free acid) Shipped in Dry Ice Q Exclusive Acetyl [1,2- 13 C] Coenzyme A lithium salt “stable isotope” Solid ARCD 1134- 1 mg . R C2C21 H38 N7O17 P3S xLi ARCD 1134- 5 mg M.W. 809.57 (free acid) Shipped in Dry Ice S Exclusive T N-Acetyl sphingosine-D- erythro “cold” Solid ARCD 0275- 5 mg M.W 341.53 ARCD 0275- 50 mg U CAS # 3102-57-6 ARCD 0275- 100 mg 13 Adenosine [ribose- C5] “stable isotope” Solid ARCD 1240- 50 mg V C5C5H13 N5O4 ARCD 1240- 100 mg M.W. 272.71 Shipped in Dry Ice W Adenosine diphospho D-glucose disodium salt “cold” Solid ARCD 0781- 5 mg X M.W. 633.31 CAS # 102129-65-7 Y Z American Radiolabeled Chemicals, Inc. , 101 ARC Drive, Saint Louis, MO 63146-3502 USA Telephone: 314-991-4545 Fax: 314-991-4692 Toll Free: 800-331-6661 Fax: 800-999-9925 1 E-mail: [email protected] Web: http://www.arc-inc.com ALPHABETICAL LISTING OF CHEMICALS Product Description Specific Solvent/ Catalog Number/ Activity Concentration Package Size A S-(5’-Adenosyl)-L-methionine “cold” Solid ARCD 0768- 5 mg (SAM) ARCD 0768- 25 mg B C15 H22 N6O5S ARCD 0768- 100 mg M.W. 398.5 ARCD 0768- 1 g CAS # 29908-03-0 C Shipped in Dry Ice D S-(5’-Adenosyl)-L-methionine chloride “cold” Solid ARCD 0767- 5 mg (SAM Chloride) ARCD 0767- 25 mg E C15 H23 ClN 6O5S ARCD 0767- 100 mg M.W. 434.9 ARCD 0767- 1 g CAS # 24346-00-7 F Shipped in Dry Ice G Aflatoxin B 1 “cold” Solid ARCD 0729- 1 mg C17 H12 O6 M.W. 312.3 H CAS # 1162-65-8 I Aflatoxin B 2 “cold” Solid ARCD 0730- 1 mg M.W. 314.3 CAS # 7220-81-7 J Aflatoxin M 1 “cold” Solid ARCD 0449- 1 mg M.W. 328.3 K CAS # 6795-23-9 L Alectinib hydrochloride “cold” 劇 Solid ARCD 1125- 1 mg . C30 H34 N4O2 HCl M.W. 519.08 M Alimta sodium salt “cold” Solid ARCD 0476- 10 mg N (Pemexetred sodium salt) ARCD 0476- 50 mg M.W. 450.41 O Almorexant “cold” Solid ARCD 1239- 1 mg C29 H31 F3N2O3 P M.W. 512.6 CAS # 913358-93-7 Q Alogliptin “cold” 劇 Solid ARCD 1118- 1 mg C18 H21 N5O2 R M.W. 339.39 CAS # 850649-61-5 S Alpelisib “cold” Solid ARCD 1186- 1 mg C18 H22 F3N5O2S T M.W. 441.47 CAS # 1217486-61-7 U AMD 3465 hexahydrobromide “cold” Solid ARCD 1160- 1 mg C24 H38 N6 6HBr V M.W. 896.07 CAS # 185991-07-5 Shipped in Dry Ice W X Y Z American Radiolabeled Chemicals, Inc. , 101 ARC Drive, Saint Louis, MO 63146-3502 USA Telephone: 314-991-4545 Fax: 314-991-4692 Toll Free: 800-331-6661 Fax: 800-999-9925 E-mail: [email protected] Web: http://www.arc-inc.com 2 ALPHABETICAL LISTING OF CHEMICALS Product Description Specific Solvent/ Catalog Number/ A Activity Concentration Package Size Amlodipine “cold” Solid ARCD 1218- 10 mg B C20 H25 ClN 2O5 M.W. 408.88 C CAS # 88150-42-9 L-Amino acid mixture “cold” 0.01N HCl ARCD 0756- 10 mg D L-Alanine (8%), L-Arginine (7%), L-Aspartic acid (8%), L-Glutamic acid 10 mg/ml (12.5%), Glycine (4%), Histidine (1.5%), L-Isoleucine (5%), L-Leucine (14%), L-Lysine (6%), L-Phenylalanine (8%), L-Proline (5%), L-Serine (4%), L-Threonine (5%), L-Tyrosine (4%), L-Valine (8%) E Exclusive F (1R,3R)-homo-ACPD “cold” Solid ARCD 0506- 10 mg ((1R,3R)-1-Amino-1-carboxycyclopentane-3-acetic acid) G M.W. 187.17 (1R,3S)-homo-ACPD “cold” Solid ARCD 0507- 10 mg H ((1R,3S)-1-Amino-1-carboxycyclopentane-3-acetic acid) ARCD 0507- 25 mg M.W. 187.17 ARCD 0507- 50 mg I (1S,3R)-homo-ACPD “cold” Solid ARCD 0508- 5 mg ((1S,3R)-1-Amino-1-carboxycyclopentane-3-acetic acid) ARCD 0508- 25 mg J M.W. 187.17 (±)-1-Aminocyclopentane- cis -1,2-dicarboxylic acid “cold” Solid ARCD 0512- 25 mg K (cis -1,2-ACPD) ARCD 0512- 50 mg L M.W. 173.17 (±)-1-Aminocyclopentane- cis -1,3-dicarboxylic acid “cold” Solid ARCD 0513- 2 mg (cis -ACPD) ARCD 0513- 10 mg M M.W. 173.17 N (±)-1-Aminocyclopentane- trans -1,2-dicarboxylic acid “cold” Solid ARCD 0514- 5 mg (trans -1,2-ACPD) ARCD 0514- 25 mg O M.W. 173.17 (±)-1-Aminocyclopentane- trans -1,3-dicarboxylic acid “cold” Solid ARCD 0515- 5 mg P (trans -1,3-ACPD) ARCD 0515- 25 mg M.W. 173.17 ARCD 0515- 100 mg Q CAS # 67684-64-4 (1S,3R)-1-Aminocyclopentane-1,3-dicarboxylic acid “cold” Solid ARCD 0517- 10 mg R ((1S,3R)-ACPD) M.W. 173.17 S CAS # 111900-32-4 (1S,3S)-1-Aminocyclopentane-1,3-dicarboxylic acid “cold” Solid ARCD 0518- 25 mg T ((1S,3S)-ACPD) ARCD 0518- 50 mg M.W. 173.17 U CAS # 111900-31-3 4-Aminohippuric acid “cold” Solid ARCD 0774- 1 g V M.W. 194.2 CAS # 61-78-9 W (R)- a-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid “cold” Solid ARCD 0522- 5 mg ((R)-AMPA) ARCD 0522- 25 mg X M.W. 186.2 CAS # 83654-13-1 Y Z American Radiolabeled Chemicals, Inc. , 101 ARC Drive, Saint Louis, MO 63146-3502 USA Telephone: 314-991-4545 Fax: 314-991-4692 Toll Free: 800-331-6661 Fax: 800-999-9925 3 E-mail: [email protected] Web: http://www.arc-inc.com ALPHABETICAL LISTING OF CHEMICALS Product Description Specific Solvent/ Catalog Number/ Activity Concentration Package Size A (RS)- a-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid “cold” Solid ARCD 0523- 1 mg ((RS)-AMPA) ARCD 0523- 5 mg B M.W. 186.2 ARCD 0523- 10 mg CAS # 77521-29-0 C (S)- a-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid “cold” Solid ARCD 0524- 1 mg ((S)-AMPA) ARCD 0524- 5 mg D M.W. 186.2 CAS # 83643-88-3 E D-(-)-2-Amino-4-phosphonobutyric acid “cold” Solid ARCD 0526- 10 mg (D-AP4) ARCD 0526- 50 mg F M.W. 183.1 CAS # 78739-01-2 G DL-2-Amino-4-phosphonobutyric acid “cold” Solid ARCD 0527- 100 mg (DL-AP4) ARCD 0527- 250 mg H M.W. 183.10 ARCD 0527- 500 mg CAS # 6323-99-5 ARCD 0527- 1 g I L-(+)-2-Amino-4-phosphonobutyric acid “cold” Solid ARCD 0528- 10 mg (L-AP4) J M.W. 183.10 CAS # 23052-81-5 K D-(-)-2-Amino-7-phosphonoheptanoic acid “cold” Solid ARCD 0529- 5 mg (D-AP7) ARCD 0529- 25 mg L M.W. 225.18 CAS # 81338-23-0 M DL-2-Amino-7-phosphonoheptanoic acid “cold” Solid ARCD 0530- 10 mg (DL-AP7) ARCD 0530- 50 mg N M.W. 225.18 CAS # 85797-13-3 O D-(-)-2-Amino-5-phosphonopentanoic acid “cold” Solid ARCD 0532- 1 mg (D-AP5) ARCD 0532- 10 mg P M.W. 197.13 CAS # 79055-68-8 Q DL-2-Amino-5-phosphonopentanoic acid “cold” Solid ARCD 0533- 10 mg (DL-AP5) ARCD 0533- 50 mg R M.W. 197.13 ARCD 0533- 100 mg CAS # 76726-92-6 S D-(-)-2-Amino-3-phosphonopropionic acid “cold” Solid ARCD 0534- 1 mg (D-AP3) ARCD 0534- 5 mg T M.W. 169.07 CAS # 128241-72-5 U DL-2-Amino-3-phosphonopropionic acid “cold” Solid ARCD 0535- 100 mg (DL-AP3) ARCD 0535- 250 mg V M.W. 169.07 CAS # 5652-28-8 W L-(+)-2-Amino-3-phosphonopropionic acid “cold” Solid ARCD 0536- 5 mg (L-AP3) X M.W. 169.07 CAS # 23052-80-4 Y Z American Radiolabeled Chemicals, Inc. , 101 ARC Drive, Saint Louis, MO 63146-3502 USA Telephone: 314-991-4545 Fax: 314-991-4692 Toll Free: 800-331-6661 Fax: 800-999-9925 E-mail: [email protected] Web: http://www.arc-inc.com 4 ALPHABETICAL LISTING OF CHEMICALS Product Description Specific Solvent/ Catalog Number/ A Activity Concentration Package Size 3-Aminopropylphosphinic acid “cold” Solid ARCD 0492- 10 mg B (3-APPA; CGP 27492) M.W.
Load more

Recommended publications
  • Pharmacokinetics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(12):292-295 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor Nermeen Ashoush a,b aClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, British University in Egypt, El- Sherouk city, Cairo 11837, Egypt. bHead of Health Economics Unit, Center for Drug Research and Development (CDRD), Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. _____________________________________________________________________________________________ ABSTRACT The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10 years. The drugs are safe, weight neutral and widely prescribed. There are currently many gliptins approved by FDA, namely sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin with several more in advanced stages of development. The gliptins may possess cardiovascular protective effects and their administration may promote β-cell survival; claims currently being evaluated in clinical and preclinical studies. The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds
    [Show full text]
  • Renato Wilberto Zilli Eficácia Em Longo Prazo Das
    RENATO WILBERTO ZILLI EFICÁCIA EM LONGO PRAZO DAS GLIFLOZINAS VERSUS GLIPTINAS NO TRATAMENTO DO DIABETES MELLITUS TIPO 2 APÓS FALÊNCIA DA METFORMINA COMO MONOTERAPIA: REVISÃO SISTEMÁTICA E METANÁLISE EM REDE Tese apresentada ao Programa de Ciências Médicas da Faculdade de Medicina da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Processos Imunes e Infecciosos Orientador: Prof. Dr. Fabiano Pinheiro da Silva (Versão corrigida. Resolução CoPGr 6018/11, de 13 de outubro de 2011. A versão original está disponível na Biblioteca da FMUSP) São Paulo 2017 Dados Internacionais de Catalogação na Publicação (CIP) Preparada pela Biblioteca da Faculdade de Medicina da Universidade de São Paulo ©reprodução autorizada pelo autor Zilli, Renato Wilberto Eficácia em longo prazo das gliflozinas versus gliptinas no tratamento do diabetes mellitus tipo 2 após falência da metformina como monoterapia : revisão sistemática e metanálise em rede / Renato Wilberto Zilli ‐‐ São Paulo, 2017. Tese(doutorado)--Faculdade de Medicina da Universidade de São Paulo. Programa de Ciências Médicas. Área de concentração: Processos Imunes e Infecciosos. Orientador: Fabiano Pinheiro da Silva. Descritores: 1.Diabetes mellitus tipo 2 2.Metanálise 3.Terapia combinada 4.Falha de tratamento 5.Metformina 6.Inibidores da dipeptidil peptidase IV 7.Transportador 2 de glucose‐sódio/inibidores 8.Empagliflozina 9.Dapagliflozina 10.Saxagliptina USP/FM/DBD ‐302/17 Esta tese de doutorado está de acordo com as seguintes normas, em vigor no momento desta publicação: Referências: adaptado de International Committee of Medical Journals Editors (Vancouver). Guia de apresentação e dissertações, teses e monografias. Elaborado por Anneliese Cordeiro da Cunha, Maria Julia de A.L.
    [Show full text]
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly
    2106 Diabetes Care Volume 38, November 2015 fi Wayne H.-H. Sheu,1 Ira Gantz,2 Safety and Ef cacy of Omarigliptin Menghui Chen,2 Shailaja Suryawanshi,2 Arpana Mirza,2 Barry J. Goldstein,2 (MK-3102), a Novel Once-Weekly Keith D. Kaufman,2 and Samuel S. Engel2 DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes Care 2015;38:2106–2114 | DOI: 10.2337/dc15-0109 OBJECTIVE This study was conducted to determine the optimal dose of omarigliptin, a once- weekly (q.w.) dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of patients with type 2 diabetes and evaluate the long-term safety of that dose. RESEARCH DESIGN AND METHODS In a multicenter, double-blind, 12-week, dose-range finding study, 685 oral antihy- perglycemic agent-na¨ıve or washed-out subjects with type 2 diabetes were random- ized to one of five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy end point was change from baseline in HbA1c, and secondary end points were 2-h postmeal glucose (PMG) and fasting plasma glucose (FPG). Analysis included all patients who received at least one dose of the study medication. Subjects who completed the base study were eligible to enter a 66-week extension study. RESULTS Once-weekly treatment for 12 weeks with omarigliptin provided dose-related reduc- 1Division of Endocrinology and Metabolism, De- partment of Internal Medicine, Taichung Veterans EMERGING TECHNOLOGIES AND THERAPEUTICS tions in HbA , 2-h PMG, and FPG.
    [Show full text]
  • Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
    Online Supplementary Content Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. doi:10.1001/jama.2016.9400. eMethods. Summary of Statistical Analysis eTable 1. Search Strategies eTable 2. Description of Included Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 3. Description of Included Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 4. Description of Included Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin Plus Sulfonylurea eTable 5. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 6. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 7. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin plus Sulfonylurea eTable 8. Estimated Global Inconsistency in Networks of Outcomes eTable 9. Estimated Heterogeneity in Networks eTable 10. Definitions of Treatment Failure Outcome eTable 11. Contributions of Direct Evidence to the Networks of Treatments eTable 12. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes Given as Monotherapy eTable 13. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes When Used in Dual Therapy (in Addition to Metformin) eTable 14. Network Meta-analysis Estimates of Comparative Treatment Effects for Drug Classes Given as Triple Therapy eTable 15. Meta-regression Analyses for Drug Classes Given as Monotherapy (Compared With Metformin) eTable 16. Subgroup Analyses of Individual Sulfonylurea Drugs (as Monotherapy) on Hypoglycemia eTable 17.
    [Show full text]
  • Mastering the Outpatient Type 2 Management Objectives
    Jorge De Jesús MD Mastering the outpatient Type 2 Management Objectives: After this presentation you will be able to recognize: .Diabetes Mellitus is a progressive disease .Prevention is possible for selected high risk individuals • Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient- specific concerns, adverse drug reactions, and contraindications • Discuss the role and timing of combination therapy in achieving A1C goals • Explain the implications of recent, large randomized clinical trials on clinical decision-making • Modifications in 2019 ADA guidelines based on recent RCT trials Individualize Choose A1c goal 7% for most patients < 7% younger with few comorbidities Older group with multiple Comorbidities could be around 8% Glucose-lowering medication in type 2 diabetes: overall approach. American Diabetes Association Dia Care 2019;42:S90-S102 10: COST !!! ©2019 by American Diabetes Association Case 1: Carmen 55 year-old female with newly diagnosed type 2 diabetes Active: she takes care of her grandchildren while their mother works On physical examination , she is alert oriented Too busy to exercise. Eats the cooperative no acute distress same food as her grandchildren Height: 64” Weight 188# BMI=33 No alcohol BP=160/100 Foot Exam : normal pulses ; normal sensory Has hypertension and sleep apnea Fundoscopy , no retinopathy A1c=7.4%; creatinine .9 mg /dL; No history of pancreatitis, no no microalbuminuria; abnormal liver function, or CHF LDL=146
    [Show full text]
  • Official Protocol Title: NCT Number: NCT02906709 Document Date
    Official Protocol Title: A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy NCT number: NCT02906709 Document Date: 10-Mar-2017 Product: MK -3102 1 Protocol/Amendment No.: 039-01 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) One Merck Drive P.O. Box 100 Whitehouse Station, New Jersey, 08889-0100, U.S.A. Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy EudraCT NUMBER: Not Applicable MK-3102-039-01 Final Protocol 10-Mar-2017 04MKJ4 Confidential Product: MK-3102 2 Protocol/Amendment No.: 039-01 TABLE OF CONTENTS SUMMARY OF CHANGES...............................................................................................
    [Show full text]
  • WO 2016/018931 Al 4 February 2016 (04.02.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/018931 Al 4 February 2016 (04.02.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/495 (2006.01) A61K 38/18 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 14/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 15/0425 10 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 28 July 2015 (28.07.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/03 1,063 30 July 2014 (30.07.2014) US kind of regional protection available): ARIPO (BW, GH, 62/195,908 23 July 2015 (23.07.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: NGM BIOPHARMACEUTICALS, INC.
    [Show full text]
  • Omarigliptin Decreases Inflammation and Insulin Resistance in A
    Hattori Diabetol Metab Syndr (2020) 12:24 https://doi.org/10.1186/s13098-020-00533-3 Diabetology & Metabolic Syndrome RESEARCH Open Access Omarigliptin decreases infammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes Sachiko Hattori* Abstract Background: Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Infammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. Methods: Whether omarigliptin has anti-infammatory efects that result in decreased levels of high-sensitivity C-reactive protein (hsCRP) and anti-insulin resistance efects that decrease levels of homeostatic model assessment of insulin resistance (HOMA-IR) were investigated. Patients were allocated to continue with daily DPP4 inhibitors (control, n 28) or to switch from daily DPP4 inhibitors to weekly omarigliptin (omarigliptin, n 56). Fasting blood and urine samples= were collected before, and every 3 months after intervention for 1 year. = Results: Omarigliptin tended to elicit reductions in fasting blood glucose (FBG), LDL-cholesterol, triglyceride, aspar- tate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), the urinary albumin-to-creatinine ratio (ACR) with logarithmic transformation (log ACR), and systolic and diastolic blood pressure, but the diferences did not reach statistical signifcance compared with control. Values for HDL-cholesterol tended to increase, but also did not reach statistical signifcance compared with control. Omarigliptin signifcantly decreased HOMA-IR, remnant-like particle cholesterol (RLP-C), and hsCRP with logarithmic transformation (log hsCRP) compared with control. However, omarigliptin did not afect hemoglobin A1c (HbA1c), body mass index (BMI), and estimated glomerular fltration rates (eGFR).
    [Show full text]
  • Pharmacy 482 Literature Review of Oral Treatment
    Med. Surg. J. – Rev. Med. Chir. Soc. Med. Nat., Iaşi – 2020 – vol. 124, no. 3 PHARMACY REVIEWS LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS Mousa Sha’at1, Cristina Mihaela Ghiciuc2, Alexandra Bujor1*, D. V. Timofte2, Alina Ștefanache1, Lăcrămioara Ochiuz1 “Grigore T. Popa” University of Medicine and Pharmacy Iasi 1. Faculty of Pharmacy 2. Faculty of Medicine *Corresponding author. E-mail: [email protected] LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS (Abstract): Type 2 non-insulin-dependent diabetes mellitus (T2DM), the most common form of diabetes that affects more than 90% of diabetic patients, is characterized by insulin re- sistance, β-pancreatic cells dysfunction, and increased hepatic glucose synthesis. The aim of the present paper was to review data on the efficacy of conventional oral dosage forms com- pared to controlled oral drug delivery systems for treating diabetes. Although the number of oral antidiabetic drugs has significantly increased in recent years, clinically there are still important limitations in terms of therapeutic efficacy, tolerability, and adverse effects, par- ticularly regarding weight gain and medium and long-term glucose control. The last genera- tion of oral pharmaceutical formulations such as modified-release tablets overcame some limitations, while injectable formulations with glucagon-like peptide-1 receptor agonists sig- nificantly increased the effectiveness of anti-diabetic medication and significantly reduced diabetes-specific comorbidities. Metformin extended-release formulation seems to be more effective than metformin conventional-release formulation in improving glyco-metabolic control, lipid profile, and levels of some adipocytokines in T2DM. Sustained-release glipiz- ide formulation increases the compliance compared to immediate-release glipizide because it seems to achieve similar glucose control with decreased insulin secretion and to decrease the frequency of hypoglycemic episodes.
    [Show full text]
  • Functional Comparisons of Three Glutamate Transporter Subtypes Cloned from Human Motor Cortex
    The Journal of Neuroscience, September 1994, 14(g): 5559-5569 Functional Comparisons of Three Glutamate Transporter Subtypes Cloned from Human Motor Cortex Jeffrey L. Arriza, Wendy A. Fairman, Jacques I. Wadiche, Geoffrey H. Murdoch, Michael P. Kavanaugh, and Susan G. Amara The Vellum Institute for Advanced Biomedical Research, Oregon Health Sciences University, Portland, Oregon 97201 Reuptake plays an important role in regulating synaptic and peripheral tissues(Christensen, 1990) and in the nervous system extracellular concentrations of glutamate. Three glutamate (Kanner and Schuldiner, 1987; Nicholls and Attwell, 1990). transporters expressed in human motor cortex, termed Transport serves a special function in the brain by mediating EAATl , EAATP, and EAAT3 (for excitatory amino acid trans- the reuptake of glutamate releasedat excitatory synapses.Glu- porter), have been characterized by their molecular cloning tamate can be reaccumulated from the synaptic cleft by the and functional expression. Each EAAT subtype mRNA was presynaptic nerve terminal (Eliasof and Werblin, 1993) or by found in all human brain regions analyzed. The most prom- glial uptake of transmitter diffusing from the cleft (Nicholls and inent regional variation in message content was in cerebel- Attwell, 1990; Schwartz and Tachibana, 1990; Barbour et al., lum where EAATl expression predominated. EAATl and 199 1). The activities of neuronal and glial transporters influence EAAT3 mRNAs were also expressed in various non-nervous the temporal and spatial dynamics of the chemical signal in tissues, whereas expression of EAATS was largely restricted other neurotransmitter systems(Hille, 1992; Bruns et al., 1993; to brain. The kinetic parameters and pharmacological char- Isaacsonet al., 1993), but such effects have not yet been dem- acteristics of transport mediated by each EAAT subtype onstrated at glutamatergic synapses(Hestrin et al., 1990; Sar- were determined in transfected mammalian cells by radio- antis et al., 1993).
    [Show full text]
  • Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes: Systematic Review and Economic Evaluation
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 21 ISSUE 2 JANUARY 2017 ISSN 1366-5278 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt and Norman Waugh DOI 10.3310/hta21020 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston,1 Olalekan Uthman,2 Ewen Cummins,1 Christine Clar,3 Pamela Royle,2 Jill Colquitt,4 Bee Kang Tan,2 Andrew Clegg,5 Saran Shantikumar,2 Rachel Court,2 J Paul O’Hare,2 David McGrane,6 Tim Holt7 and Norman Waugh2* 1McMDC, Harrogate, UK 2Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK 3Berlin, Germany 4Effective Evidence, Waterlooville, UK 5University of Central Lancashire, Preston, UK 6Queen Elizabeth University Hospital, Glasgow, UK 7University of Oxford, Oxford, UK *Corresponding author Declared competing interests of authors: David McGrane has spoken at educational meetings sponsored by AstraZeneca, Eli Lilly, Sanofi, MSD, Takeda Pharmaceutical Company, Novo Nordisk, Janssen, and has served on Advisory Boards for Eli Lilly, Sanofi, Novo Nordisk. J Paul O’Hare has received lecture fees, advisory board meeting fees, and grants for research from Novo Nordisk and Sanofi. All fees are paid through University of Warwick to fund access to insulin projects in sub-Saharan Africa. Published January 2017 DOI: 10.3310/hta21020 This report should be referenced as follows: Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al.
    [Show full text]
  • OCD Candidate Gene SLC1A1/EAAT3 Impacts Basal Ganglia-Mediated Activity and Stereotypic Behavior
    OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior Isaac D. Zikea, Muhammad O. Chohanb, Jared M. Kopelmanc,d,e, Emily N. Krasnowb, Daniel Flickerf,g,h,i, Katherine M. Nautiyalj,k, Michael Bubserl, Christoph Kellendonkm,n,o,p, Carrie K. Jonesa,l, Gregg Stanwoodq, Kenji Fransis Tanakar, Holly Mooreb, Susanne E. Ahmaric,d,e,1, and Jeremy Veenstra-VanderWeeleb,m,n,1 aDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232; bNew York State Psychiatric Institute, New York, NY 10032; cDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260; dCenter for Neuroscience Program, University of Pittsburgh, Pittsburgh, PA 15260; eCenter for the Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA 15260; fHoward Hughes Medical Institute, Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114; gCenter for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114; hDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; iBroad Institute, Cambridge, MA 02142; jDepartment of Psychiatry, Columbia University Medical Center, New York, NY 10032; kDivision of Integrative Neuroscience, New York State Psychiatric Institute, New York, NY 10032; lVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232; mDepartment of Psychiatry, Columbia University Medical Center, New York, NY 10032; nSackler Institute for Developmental Psychobiology, Columbia University Medical Center, New York, NY 10032; oDepartment of Anesthesiology, Columbia University Medical Center, New York, NY 10032; pDivision of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032; qDepartment of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304; and rDepartment of Neuropsychiatry, School of Medicine, Keio University, Tokyo 108-8345, Japan Edited by Susan G.
    [Show full text]